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A rational approach to heparins
HC Hemker and S B6guin
Cardiovascular Research Institute, Depaftrnent of Biochemistry, University of Limburg, P.O. Box 616, NL-620O MD Maastricht, The Netherlands
Abstract. It is shown why the current practice of expres-
sing heparin activity in International Units is not an ade-
quate way to deal with the situation that arises after
injection of low molecular weight heparins. An alternati-
ve approach is proposed. It is taken into account that the
fraction of a low molecular heparin that binds with high
afftnity to antithrombin III contains rwo fundamentally
different components : the material above the critical
chainlength of 17 sugar units that has both anti-factor
Xa activity and antithrombin activity (ACLM) and the
material below that length with anti-factor Xa activity
only (BCLM). It is shown how the levels of ACLM and
BCLM in a plasma sample can be determined and
expressed in ltglml.
Une approche rationnelle des h6parines
R6sum6. Il est dimontd que la pratique habituelle
d'exprimer l'activit6 de l'h6parine en Unitis Internatio-
nales n'est pas une fagon adiquate de ripondre d la
situation qui fait suite d l'injection des hiparines de bas
poids mol4culaire. Une autre mdthode est proposde. Elle
tient compte dufait que lafractiond'une hdparine de bas
poids moliculaire qui se lie avec une forte affiniti d
l'antithrombine III contient deux composants radicale-
ment dffirents : celui dont la longueur de la chatne est
supdrieure d 17 unitis monosaccharidiques a une activi-
tE anti-facteur Xa et antithrombine et celui dont la lon-
gueur est infdrieure et qui ne posslde qu'une activitd
anti-facteur Xa. On d€montre comment ces deux activitds
peuvent Atre mesurdes dans un 4chantillon de plasma et
exprimdes en ltglml.
Key words : (Low molecular weight) heparin - Anti-
thrombin activity - Antithrombin III - Anti-factor Xa
ac tivity - P entasac c haride
It is not necessary for an efficient treatment to be based
on rational reasoning, nor will a therapy automatically
follow from sufficient scientific knowledge of a disease.
Psychotherapy has its therapeutic successes even though
Popper explains us that no hard science is involved and
no cure for AIDS has as yet evolved despite our detailed
knowledge of its cause. That is what makes the difference
between the art of the doctor and the science of medicine.
Yet there is a supreme reason for trying to push medi-
cine as far as possible in the direction of the natural
sciences : reproducibility. The failure of an ununderstood
therapy may be due to any reason, from fundamental
misconception (e.g. homeopathy) to stochastic variation,
and trial and error is the only way to improvement. The
failure of a therapy with a sound scientific basis is open
to analysis and allows a design for amelioriation.
For many years and up to the present moment theOffprint requests.' HC Hemker
6effedtiveness of heparin therapy has been recognised but
not understood. A role of the anticoagulant action of
heparin is our savest guess. Indeed the evidence for a
central role of thrombin formation in the genesis of
thrombosis is becoming overwhelming. If not recent
research had shown how intricately platelet physiology is
related to thrombin formation, it would hardly have been
elegant to stress this point in an article dedicated to a
scientist who has so ardently devoted his career to the
blood platelet.
If we want to test the hypothesis that the anticoagu-
lant action of heparin is the therapeutic one, then correct
quantitation of this effect is the first requirement. This is
a field fraught with difficulties, to some of which we
think to have found rational solutions recently.
As long as unfractionated heparin was the unique spe-
cies available the quantitation of its effects was relatively
straightforward because in the different preparations the
ratio of the different activities was fairly constant. Hence,
if one measured e.g. an anti-factor Xa (aXa) dependent ex
vivo test, it would correlate with any antithrombin (aIIa)
dependent in vivorcP effect, because there wBs a fixed
relation between the two activities. With the advent of
low molecular heparins however, it became possible to
vary the aXa- and alrg activities independently in diffe-
rent heparin preparations. The convenient covariation of
the two different anticoagulant activities was lost. Yet
quantification continued to be carried out in terms of one
biological effect only, often the anti-factor Xa activity,
altematively the aPTT, the heptest, the thrombin time etc.
The carry over, onto low molecular weight heparins, of
habits that were satisfying for unfractionated heparins,
has been at the basis of much confusion. At this moment,
based on the insights from recent research, it seems pos-
sible to design a more rational approach.
The biochemical basis of heparin action
The biochemical basis of heparin action is the fact that it
catalyzes the inactivation of proteases by inhibitors avai-
lable in the plasma.
As an example we take the inactivation of factor Xa
(F.Xa) by antithrombin III (AT III).
F.Xa + AT III k > inactive product
Usually there is much more AT III than FXa so that the
final concentration of this reactant will not be very diffe-
rent from,the starting concentrationl. Therefore the reac-
tion will obey pseudo first order kinetics i.e. the reaction
velocity (v) is proportional to the initial concentration of
AT III and the temporal concentration of F.Xa. Elemen-
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tary reaction kinetics learns that in this situation F.Xa
activity will disappear logarithmically. That is to say that
its inactivation is characterized by a half-life time (tt2)
that is inversely proportional to the reaction constant (k)
and to the initial concentration of AT III. The AT III
concentration multiplied by k govems the rate of decay
of enzyme activity. It therefore is often refered to as the
decay constant: ko"" . The dimension of ko"" is the inverse
minute, because it is proportional to the inverse of the
half-life time measured in minutes2.
In order to be active in catalysing AT III mediated
reactions, heparin has to contain the specific pentasac-
charide through which the binding to AT III is mediated
[6]. Additionally for catalysing the inhibition of thrombin
it is necessary that the chainlength is not shorter than 18
monosaccharide units fI,2,7-9, 14, 18, 191. In every
heparin preparation one can therefore distinguish the
high affrnity material (HAM), that contains the pentasac-
charide versus the low affinity material (LAM) that does
not. Within the HAM fraction one can again distinguish
between the material above the critical chainlength
(ACLM) that is able to act on both thrombin and factor
Xa inactivation. and the material belo* the critical chain-
length (BCLM) that only acts on factor Xa [5, 12]. One
can determine the specific anti-factor Xa activity of a
heparin, which is the increase of ko"" of factor Xa
brought about in plasma by I pglml reaction medium of
the heparin in question. One can also determine the spe-
cific antithrombin activity of a heparin, which, analo-
gousl ! ,  is  the increase of  the ko""  of  thrombin
in plasma brought about by 1 pglml of the heparin [12].
Because ku". is proportional to the concentration of AT
III it should be normalised to plasma containing 1 pM of
AT III by dividing it through the actual AT III concentra-
tion of the plasma used.
The specific anti-factor Xa activity is caused by the
HAM molecules, the specific antithrombin activity by
the ACLM molecules. Later we will discuss what else
influences these constants.
Studying a large series of different heparins, we
found that the specific activities of all ACLM prepara-
I This holds at any given instant during the clotting of blood when free
F.Xa (and thrombin) is available. The peak F.Xa concentration in clot-
ting plasma is -20 nM, that of thrombin -300 nM, whereas AT Itr is
present at concentrations > 2 PM.It does not mean that the concentra-
tion of AT Itr remains constant during the whole of the clotting process.
In serum the AT III concentration will equal roirghly the AT III concen-
tration of plasma minus the prothrombin concentration of plasma
2 The relevant formulas are
C,=Co. eh*'t or Ln C,=Ln Qo - kdo t. kd@ = k. tATtrn.
From this it follows that the half-life time t,, = Ln 2ka*. The first for-
mula can also # written as C,=Co. |fr.Z)th;:whichimilediately shows
the relation between halflife time and semilogarithmic decay
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tions, obtained from different types of LMWH, vary
within narrow limits, both with regard to the aIIa and to
the aXa activity (e.g.the specific aIIa in the ACLM frac-
tions of ten different LMWH preparations was found to
be l4.l + 2.7 min-r (ttg/mD/ttM AT III (calculated from
data in [11]). The same holds for the specific aXa activity
of the BCLM preparations. This means that the diffe-
rences between different heparins are primarily due to
thEir HAM, ACLM ANd BCLM CONtENI.
It is interesting to see that ACLM is more potent than
BCLM is. In a mixture ACLM will as a rule overshadow
the activities of BCLM, unless the proportion of BCLM
becomes very large. This is the explanation of the obser-
vation that most LMWHs, like UFH inhibit free throm-
bin in clotting blood primarily by scavenging thrombin
already formed, the inhibition of prothrombin conversion
being much less important [0]. This group of heparins
we called S (standard UFH-like) heparins. Only those
preparations that do not or hardly contain ACLM, will
act via inhibition of prothrombin conversion. We called
them P (pentasaccharide-like) heparins [10].
Although in vitro BCLM is much less potent than
ACLM, it may gain in importance in vivo. In the first
place platelet factor 4 (PF4), released from activated pla-
telets can completely neutralise ACLM but will not inac-
tivate BCLM as thoroughly [14]. In the second place the
biological half-life time in the circulation is shorter the
longer the chainlength is. Therefore BCLM survives lon-
ger in the circulation than ACLM. After injection there is
a "heparin fractionation in vivo that favours the persis-
tence of BCLM molecules [12].
How to determine ACLM and BCLM levels in plasma
In plasma the aXa activity and the antithrombin activity
can be readily determined. If the specific activities of the
heparin injected are known one can readily obtain the
ACLM level by deviding the increase of the ko"" of
thrombin caused by the heparin through the specific anti-
thrombin activity of that heparin [12]. One should be
aware of the fact that in this way one measures the
amount of ACLM molecules active in the plasma, i.e.
bound to AT III. As we will see later this is not automati-
cally the same as the concentration of those molecules in
the plasma. Here it suffices to say that it is anyhow the
active concentration. The level of all active HAM mole-
cules is obtained by deviding the increase of the ko"" of
factor Xa by the specific anti-factor Xa activity. The
level of BCLM can then be obtained by subtraction of
the HAM level and the ACLM level [2]. Preliminary
results show that, after subcutaneous injection, ACLM
disappears with a higher velocity than BCLM. This alone
makes it clear that the pharmacology of a LMWH cannot
be treated as the pharmacology of one single chemical
species and that it is necessary to at least recognise the
two species mentioned. This however raises the question
: is this sufficient or are there additional complications ?
Is it necessary to reckon with other effects ?
Other clotting factors and inhibitors
In plasma there are more clotting proteases than only
thrombin and factor Xa and there is at least one more
heparin-dependent inhibitor. Yet, in our opinion, in a
first attempt to rationalisation, we may probably restrict
ourselves to two variables that we discussed above.
Although the factors of the contact system are not
insensitive to heparin action [7], the effect of the normal
doses of heparin on this system are negligible and can for
all practical pulposes be disregarded if we restrict our-
selves to the effects ofprophylactic and therapeutic hepa-
rin concentrations [15].
Factor IXa is stable in plasma until heparins are added
[16]. This anti-factor IXa effect contributes significantly
to the anticoagulant effect of heparin in the intrinsic sys-
tem [4]. We did not yet investigate LMWHs in this res-
pect. The available data [13] suggest that the Mw depen-
dency of the aIXa action is identical to that of the aIIa
activity. If this is true, then there is no need for a separate
consideration of the aIXa effect if one wants to quantitate
the heparin effect because it will covariate, and therefore
be adequately rendered by the antithrombin effect.
Heparin cofactor II (HC II) is an inhibitor of throm-
bin only, that is stimulated by heparin. Tenfold higher
concentrations of heparin are however needed for this
factor than for AT III [20]. Again the effect of this factor
may be disregarded unless very high doses of heparin are
given (e.g. artificial circulation).
H eparin binding proteins
In plasma AT III is not the only heparin binding protein
(HBP). Histidine rich glycoprotein and many other plas-
ma proteins compete with AT III for circulating heparin.
This explains why the effect of heparin is proportional to
the concenffation of AT III, even though AT III (- 2 trM)
is present in large excess over the highest possible
concentration of heparin (l U/ml = 0.3 pM). In a purified
system this would lead to practically complete binding of
all heparin and adding more AT III would not apprecia-
bly change the situation. In plasma, with much compe-
ting proteins present, increasing (decreasing) the concen-
tration of AT III will proportionally ameliorate (worsen)
8its position in the competition.
The binding to the other proteins is however not via
the specific pentasaccharide of the heparin. This means
that it must be possible to set free anticoagulant heparin
from heparin binding proteins by adding non-anticoagu-
lant, low affinity heparin (LAM). A rough estimate tells
that about 40 Vo of the potentially active heparin indeed
binds to AT III. The active concentration of HAM, calcu-
lated by the procedures mentioned above is therefore
4O Vo of the real concentration.
The ffict of platelets
Upon activation platelets release PF4, a protein that binds
strongly to heparins. The maximal amount of PF4 relea-
sed in normal platelet rich plasma (PRP) can neutralize
some 0.4 U/ml of unfractionated heparin I3l. All ACLM
can be readily inactivated by PF4 but BCLM binds with
significantly lower affinity and cannot be inhibited com-
pletely. LMWHs therefore retain some activity, and espe-
cially BCLM, i.e. anti-factor Xa activity in the presence
of activated platelets. What difference this makes as to
their efficiency as antithrombotics is anybody's guess.
One can imagine that in and around platelet rich thrombi,
where the PF4 concentrations must be enormous, a
LIvtWH that retains some of its activity should be more
efficient than UFH. If this is true then the Choay penta-
saccharide should be a more efficient antithrombotic than
could be predicted from its anticoagulant action in platelet
poor plasma. One can however also reason that the prima-
ry use of a heparin is to catch thrombin, so that no plate-
lets are activated. If this is a valid reasoning, then ACLM
would be a beffer preventive drug than BCLM, whereas
BCLM would be better in curative situations.
Simple and composite effects of heparins
The simple and direct effects of heparin in plasma are the
catalysis of thrombin and factor Xa inhibition. The cata-
lysis of thrombin inhibition is simply a function of the
amount of circulating ACLM and its specific activity.
Factor Xa inhibition is a function of the total amount of
active HAM, i.e. of both the ACLM and the BCLM
concentration. If we denote the specific activities by S,
with a subscript indicating the relevant factor, then :
aIIa = Sz.[ACLM] and (a)
aXa = Sro.[ACLM] + S'ro.[BCLM] (b)
Above we discussed how these formulas can be used to
obtain the ACLM and BCLM concentrations if the speci-
fic activities are known.
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Any effect of heparin on a biological variable is a
consequence ofits aIIa and/or aXa action. For the sake of
simplicity we assume the aIXa action to be adequately
rendered by the antithrombin action (see above). This
means that e.g. the inhibition (prolongation) of the APTT
(P(aptt)) is dependent upon both actions :
P(aptt) = p. aIIa + q. aXa
A combination of the above formulas (a, b and c) shows
that :
P(aptt) = p'.ACLM + q'.BCLM (d)
where p' and q' are combinations of p, q and the relevant
specific activities. Because a pentasaccharide that has only
aXa activity is a poor inhibitor of the APTT we can guess
that p' is considerably greater than q' but further quantita-
tion is impossible at the moment. This formula says sim-
ply that the outcome of a test like the APTT is dependent
upon both the concentration of ACLM and of BCLM.
What holds for the APTT will hold for any other bio-
logical effect, but the coefficients (p' and q') will be dif-
ferent. If, e.g. we look at the inhibition of thrombus for-
mation in a patient by heparin, it will again be a function
of the ACLM and the BCLM concentrations, analogous
to formula d. There is however no reason to assume that
it will be precisely as dependent upon ACLM and BCLM
concentrations as the APTT is. In other words, the coeffi-
cients (p' md q') in equation d will be different when this
formula renders the APTT than when it is modified to
render the antithrombotic action. The same will hold for
the bleeding tendency caused by a heparin. Again the
coefficients will differ from both those for the APTT and
those for the antithrombotic activity.
It is even the bread and butter of heparin therapy that
the coefficients for the bleeding tendency are smaller then
those for antithrombotic action. This defines the therapeu-
tic window. The clinically relevant coefficients will
always be different from those goveming the APTT or any
other clotting test. Therefore any single exvivo laboratory
variable is incommensurable with antithrombotic or blee-
ding actions and it is fundamentally impossible to judge
the effect of a heparin on basis of any single test only.
The approach that we propose is to determine ACLM
and BCLM concentrations according to the principles
exposed in previous paragraphs. Then we can relate anti-
thrombotic and bleeding effects to those concentrations.
In the meantime for a series of biological tests the depen-
dence on ACLM and BCLM concentrations can be deter-
mined. That laboratory determination that reacts more or
less in the same way as thrombosis inhibition or bleeding
will then be the test of choice for routine monitoring of
(c)
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patients. It may seem difficult to determine the influence
of pure ACLM and BCLM on haemostasis and thrombo-
sis, but this is not necessarily the case, because the high
affinity fraction of unfractionated heparin is a good
model for ACLM and the synthetic AT III binding penta-
saccharide is a model for BCLM.
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